1. Pink Sheet

COVID Vaccine Transition Planning: Price Does Not Come Up At ACIP

 
• By Michael McCaughan

US CDC is starting to prepare for the transition of COVID vaccine deliver to more traditional commercial channels. It is noteworthy that the first discussion of what will change did not include any talk of prices.

vaccines and money
Despite the headlines, policymakers see considerable ongoing value in COVID vaccinations even at the planned commercial prices. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The US Centers for Disease Control & Prevention and Food & Drug Administration are taking the first big steps towards the transition in COVID vaccine delivery into more traditional channels as the Public Health Emergency phase of the pandemic winds down.

The immediate changes include moving to bivalent-only formulations of the two mRNA vaccines, Pfizer Inc./BioNTech SE’s Comirnaty and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 
• By Sarah Karlin-Smith

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.

Novaxovid And mNexspike Reviewers

 
• By Bridget Silverman

Pink Sheet Drug Review Profile feature listing FDA staff who conducted the reviews of Novavax and Moderna's post-pandemic COVID-19 vaccines

GLP-1s In Crosshairs As Employers Worry About Health Costs – And Their Own Reliance On Rebates

 
• By Cathy Kelly

Business Group on Health annual employer survey highlights fast-growing Rx costs, led by the GLP-1 drugs, and payer strategies for controlling them. Policy prescriptions are unclear, though, since employers are loath to leave PBMs and nervous about pending changes to Medicare and Medicaid.